Abstract
A simple, specific and sensitive derivatization with monobromobimane (mBrB) and the corresponding HPLC-fluorescence quantitation method for the analysis of bucillamine in human plasma was developed and validated. The analytical procedure involves a simple protein precipitation, pre-column fluorescence derivatization, and separation by reversed-phase high performance liquid chromatography (RP-HPLC). The calibration curve showed good linearity over a wide concentration range (50 ng/mL to 10 μg/mL) in human plasma (r2 = 0.9998). The lower limit of quantitation (LLOQ) was 50 ng/mL. The average precision and accuracy at LLOQ were within 6.3% and 107.6%, respectively. This method was successfully applied to a pharmacokinetic study after oral administration of a dose (300 mg) of bucillamine to 20 healthy Korean volunteers.
| Original language | English |
|---|---|
| Pages (from-to) | 2130-2134 |
| Number of pages | 5 |
| Journal | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences |
| Volume | 877 |
| Issue number | 22 |
| DOIs | |
| State | Published - 15 Jul 2009 |
| Externally published | Yes |
Keywords
- Bucillamine
- Monobromobimane
- Pharmacokinetics
- Pre-column fluorescence derivatization
- RP-HPLC
Fingerprint
Dive into the research topics of 'Development and validation of a reversed-phase fluorescence HPLC method for determination of bucillamine in human plasma using pre-column derivatization with monobromobimane'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver